As shown in figure 10, tumour response to anti-CTLA-4 and anti-PD-L1 therapy is sensitive to effector T-cell apoptosis, Treg/MDSC level in the tumour, T-cell clonality and the effect of checkpoint expression by Tregs on effector T cells and mAPCs, in addition to the parameters discussed above. This evidence concerns the gene CD274 and neoplasm.